Execs On The Move: An Eli Lilly President Departs; Finance Positions Filled At NuVasive And DBV Technologies
The president of Eli Lilly USA departs for CEO post at FibroGen, a developer of medicines for anemia, fibrotic disease and cancer; a former Mallinckrodt exec is CFO of NuVasive, a maker of products for spine surgery; DBV Technologies, an investigator of treatments for food allergies, also adds a CFO; and more.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.